Navigation Links
Mark S. Levine Joins Minerva Neurosciences as VP and General Counsel
Date:8/18/2014

CAMBRIDGE, Mass., Aug. 18, 2014 /PRNewswire/ -- Minerva Neurosciences (NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Mark S. Levine has been appointed vice president and general counsel. In this position, Mr. Levine will be responsible for the company's legal affairs and will report to Rogerio Vivaldi, MD, MBA, Minerva Neurosciences' president and chief executive officer. 

Mr. Levine has more than 17 years of experience as a corporate and commercial attorney. His expertise includes contractual matters, mergers & acquisitions, litigation management, and corporate governance and regulatory compliance. He has served in a number of senior legal positions including as assistant general counsel of athenahealth, Inc., a cloud-based service provider to medical practices and health systems. He was also formerly associate general counsel of Clinical Data, Inc., a specialty pharmaceutical company, senior legal counsel of Wheelabrator Technologies, Inc., a renewable energy generating company, and associate general counsel of Xpedior Incorporated, an Internet consulting company. Mr. Levine holds a bachelor of arts degree from Binghamton University, SUNY, and a juris doctor from Washington University in St. Louis.

"As we work to advance our pipeline of novel therapies for the treatment of neuropsychiatric diseases, we are expanding the Minerva team to bring the full range of business and drug development and commercialization expertise we need to continue to build momentum. Mark Levine brings Minerva a wealth of targeted legal experience to support our business development initiatives on all fronts, and he will play a pivotal role in planning and executing our business strategy in the years ahead," said Mr. Vivaldi.

About Minerva
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. The company was incorporated under the name Cyrenaic Pharmaceuticals, Inc. on April 23, 2007. In November 2013, it merged with Sonkei Pharmaceuticals, Inc. and the combined company was renamed Minerva Neurosciences, Inc. 

Forward-Looking Safe-Harbor Statement:

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to management's ability to successfully achieve its goals. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors including, without limitation, management's ability to successfully achieve its goals. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission which are available on the SEC website at www.sec.gov. In addition, please note that any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of the date hereof. We undertake no obligation to update these statements as a result of new information or future events.

Media contact:
Jen Ringler
Berry & Company Public Relations
212.253.8881
jringler@berrypr.com

Investor contact:
Renee Leck
Stern Investor Relations
212.362.1200
renee@sternir.com


'/>"/>
SOURCE Minerva Neurosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
2. Levine Leichtman Acquires Champion Manufacturing
3. Nutrilys Del Mar Joins Health Forces With LAPD Underwater Dive Unit
4. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
5. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
6. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
7. David F. Harty Joins Systech International as Vice President
8. Jim DuCharme Joins Prime Therapeutics as Chief Financial Officer
9. Ted Pacha Joins Pinnaclife as President of its Healthcare Distribution Division
10. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
11. Anthony Creed Joins DDSTUDIO As GM, Experience Design
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):